Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Executive Summary
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
You may also be interested in...
Scottish HTA Reverses No For Yescarta
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.